Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for shares of Keros Therapeutics in a note issued to investors on Thursday, February 27th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.27) per share for the quarter, up from their prior estimate of ($1.51). HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. HC Wainwright also issued estimates for Keros Therapeutics' Q2 2025 earnings at ($1.39) EPS, Q3 2025 earnings at ($1.30) EPS, Q4 2025 earnings at ($1.41) EPS, FY2025 earnings at ($5.36) EPS, FY2026 earnings at ($6.02) EPS, FY2027 earnings at ($6.63) EPS, FY2028 earnings at ($4.37) EPS and FY2029 earnings at ($2.50) EPS.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.
A number of other equities research analysts have also recently weighed in on KROS. Scotiabank lowered their price target on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a report on Thursday, January 16th. Piper Sandler lowered their price target on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a report on Friday, January 17th. William Blair cut Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Wells Fargo & Company lowered their price target on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. Finally, TD Cowen cut Keros Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.33.
View Our Latest Analysis on Keros Therapeutics
Keros Therapeutics Stock Up 2.2 %
Shares of KROS traded up $0.26 on Monday, reaching $11.93. The stock had a trading volume of 826,079 shares, compared to its average volume of 1,564,872. The firm has a market capitalization of $483.90 million, a PE ratio of -2.29 and a beta of 1.39. The firm has a 50-day moving average of $12.10 and a 200 day moving average of $38.63. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $72.37.
Institutional Investors Weigh In On Keros Therapeutics
Several hedge funds have recently made changes to their positions in the business. FMR LLC boosted its holdings in shares of Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company's stock worth $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Keros Therapeutics by 5.4% during the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after purchasing an additional 100,691 shares during the last quarter. Alkeon Capital Management LLC boosted its holdings in shares of Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after purchasing an additional 298,694 shares during the last quarter. Braidwell LP boosted its holdings in shares of Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after purchasing an additional 1,187,199 shares during the last quarter. Finally, Darwin Global Management Ltd. boosted its holdings in shares of Keros Therapeutics by 10.7% during the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock worth $26,707,000 after purchasing an additional 163,403 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
